Want To Bet On Ozempic, Wegovy Success? Defiance Introduces Leveraged ETF To Capture Novo Nordisk Momentum
Want To Bet On Ozempic, Wegovy Success? Defiance Introduces Leveraged ETF To Capture Novo Nordisk Momentum
On Tuesday, Defiance ETFs introduced (NASDAQ:NVOX), the first single-stock leveraged ETF focused on Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO).
週二，Defiance etf推出了(NASDAQ:NVOX)，這是首個專注于丹麥製藥巨頭諾和諾德A/S (NYSE:NVO)的單隻股票槓桿etf。
The ETF offers retail investors double the daily long exposure to Novo Nordisk's stock price changes without requiring a margin account, presenting an innovative trading option.
該etf爲散戶投資者提供了對諾和諾德股價變動的每日雙倍長頭寸曝光，而無需開立按金帳戶，展現了一種創新的交易選項。
However, NVOX carries heightened risk due to its single-stock nature and does not invest directly in Novo Nordisk shares.
然而，由於NVOX的單隻股票性質，它承載着更高的風險，並且並不直接投資於諾和諾德的股票。
Also Read: Big Pharma Pushes To Revise Biden-era Medicare Drug Price Negotiation Law Under Trump
另請閱讀：大型製藥公司推動修訂拜登時代的醫療保險藥品價格談判法，特朗普時代未能成功。
Sylvia Jablonski, CEO of Defiance ETFs, emphasized the strategic importance of NVOX, highlighting Novo Nordisk's central role in the booming weight loss market.
Defiance etf的首席執行官西爾維婭·雅布隆斯基強調了NVOX的戰略重要性，突出了諾和諾德在蓬勃發展的減重市場中的核心角色。
The company produces the popular drugs Ozempic and Wegovy, which have positioned it as a key player in an industry with significant growth potential.
該公司生產了流行的藥品Ozempic和Wegovy，使其在一個具有顯著增長潛力的行業板塊中扮演了關鍵角色。
Novo Nordisk reported that in the third quarter of 2024, Wegovy sales reached 17.30 billion Danish kroner, up 81%, and Ozempic sales increased 26% at constant currency to 29.80 billion Danish kroner.
諾和諾德報告稱，在2024年第三季度，Wegovy的銷售額達到173億丹麥克朗，同比增長81%，而Ozempic的銷售額在不變貨幣的情況下增加了26%，達到298億丹麥克朗。
Jablonski described NVOX as a tool for investors looking to capitalize on this multi-trillion-dollar opportunity.
雅布隆斯基將NVOX描述爲一個工具，供希望抓住這個多萬億美元機會的投資者使用。
Established in 2018, Defiance ETFs specializes in income and thematic investing, offering products tailored for tactical trading opportunities. Its suite of ETFs spans disruptive technologies such as artificial intelligence and quantum computing.
Defiance ETFs成立於2018年，專注於收益和主題投資，提供針對戰術交易機會量身定製的產品。其etf產品涵蓋了包括人工智能和量子計算概念在內的顛覆性技術。
In August, Defiance ETFs introduced (NYSE:LLYX) the Defiance Daily Target 2X Long LLY ETF, which seeks daily leveraged investment results of two times (200%) the daily percentage change in the share price of Eli Lilly And Co (NYSE:LLY).
在8月，Defiance ETFs推出了（紐交所：LLYX）Defiance Daily Target 2X Long LLY etf，該etf旨在實現Eli Lilly And Co（紐交所：LLY）股價每日漲幅的兩倍（200%）的槓桿投資收益。
According to research published in JAMA Network Open, the use of anti-obesity medications, including glucagon-like peptide-1 receptor agonists, was associated with lower incidence and recurrence of alcohol use disorder.
根據JAMA Network Open發佈的研究，使用抗肥胖藥物，包括胰高血糖素樣肽-1受體激動劑，與酒精使用障礙的發生率和複發率降低相關聯。
Price Action: NVO stock is up 2.02% at $110.86 during the premarket session at last check Tuesday.
價格動態：NVO股票在週二的盤前交易中上漲2.02%，報$110.86。
- PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program
- PTC Therapeutics與諾華達成價值約30億的許可協議，涉及亨廷頓病項目。
Photo via Shutterstock
圖片來自shutterstock
譯文內容由第三人軟體翻譯。
